Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become central to the management of obesity, especially in the current climate with increasing rates of adiposity-related morbidity and mortality globally, supported by a strong evidence base from large cardiovascular outcome trials. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.